

## LIST OF FIGURES

<b>Figure 2.1</b> A schematic representation of autoimmune events that occurs in autoimmune hypothyroidism/ Hashimoto's thyroiditis. ....	15
<b>Figure 3.1</b> Anti-TPO antibody levels in autoimmune hypothyroidism patients and controls.....	37
<b>Figure 3.2</b> Anti-TPO antibody levels in autoimmune hypothyroidism patients based on gender.....	38
<b>Figure 3.3</b> Anti-TPO antibody levels in autoimmune hypothyroidism females and onset of age. ....	39
<b>Figure 4.1</b> PCR-RFLP analysis of CTLA4 exon 1 +49 A/G and 3' UTR CT60A/G and TG E33 polymorphisms. ....	50
<b>Figure 4.2</b> Relative gene expression of flCTLA4 and sCTLA4 in controls and autoimmune hypothyroidism patients.....	57
<b>Figure 4.3</b> Genotype - phenotype correlation of exon 1 +49A/G and 3' UTR CT60A/G polymorphisms of flCTLA4 and sCTLA4 in controls and autoimmune hypothyroidism patients.....	58
<b>Figure 4.4</b> Ratio of sCTLA4 and flCTLA4 mRNA expression in controls and autoimmune hypothyroidism patients.....	60
<b>Figure 4.5</b> Ratio of sCTLA4 and flCTLA4 mRNA expression with respect to +49A/G and CT60A/G genotypes in controls and patients. ....	61
<b>Figure 5.1</b> Synthesis scheme of HA-PEI and OA-PEI.....	73
<b>Figure 5.2</b> Synthesis scheme of $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI.....	74
<b>Figure 5.3</b> FTIR spectra of A) PEI 10 KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI. ....	91
<b>Figure 5.4</b> $^1\text{H}$ NMR spectra of A) PEI, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI.....	95
<b>Figure 5.5</b> Acid-base titration of PEI, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI. ....	97
<b>Figure 5.6</b> Buffer capacity of PEI, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI in pH range 4 to 11. ....	98
<b>Figure 5.7</b> pAL119-mCTLA4-IGHG1 plasmid circular map. ....	100
<b>Figure 5.8</b> pAL119-mCTLA4-IGHG1 plasmid circular detailed map. ....	101

<b>Figure 5.9</b> Mechanism of action of CTLA4-IG protein translated from pAL119-mCTLA4-IGHG1 plasmid. ....	102
<b>Figure 5.10</b> pEGFP-N1 plasmid detailed circular map.....	104
<b>Figure 5.11</b> Gel electrophoresis analysis of A) pAL119-mCTLA4-IGHG1 digested by XbaI B) pAL119-mCTLA4-IGHG1 digested by KpnI C) DNA marker (HiMedia) D) pAL119-mCTLA4-IGHG1 undigested. ....	105
<b>Figure 5.12</b> Gel electrophoresis analysis of pAL119-mCTLA4-IGHG1 for minimum detectable amount determination. ....	105
<b>Figure 5.13</b> Size of polyplexes prepared from PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI in 150mM NaCl, pH 7.4.....	106
<b>Figure 5.14</b> TEM images of polyplexes prepared from A) PEI 10KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI in 150mM NaCl, pH 7.4 at N/P ratio 12. ....	108
<b>Figure 5.15</b> Size of polyplexes prepared from A) PEI 10KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI in 150mM NaCl, pH 7.4 at N/P ratio 12 using DLS and TEM analysis (Comparative analysis).....	110
<b>Figure 5.16</b> Zeta potential of polyplexes prepared from A) PEI 10KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI in 150mM NaCl, pH 7.4. ....	111
<b>Figure 5.17</b> Gel retardation assay of polyplexes prepared from A) PEI 10KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI at N/P ratios 0, 0.5, 0.75, 1, 2, 4, 8 and 12.....	113
<b>Figure 5.18</b> Hemolysis analysis of PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino- HA-PEI and $\omega$ -amino-OA-PEI at various concentrations using Washed RBCs. ....	114
<b>Figure 5.19</b> Hemolysis analysis of PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino- HA-PEI and $\omega$ -amino-OA-PEI at various concentrations using Whole Blood. ....	115
<b>Figure 5.20</b> Viability of HEK 293 cells, 4 hr after treatment of PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI at various concentrations.....	116
<b>Figure 5.21</b> Viability of HEK 293 cells, 24 hr after treatment of PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI at various concentrations.....	117
<b>Figure 5.22</b> Viability of HEK 293 cells after treatment of polyplexes prepared from PEI 10KDa, HA-PEI, OA-PEI, $\omega$ -amino-HA-PEI and $\omega$ -amino-OA-PEI at N/P ratio 12.....	118

<b>Figure 5.23</b> Fluorescence microscopy images of HEK 293 cells treated with A) Naked pEGFP-N1, and polyplexes prepared at N/P ratio-12 using B) 10 KDa PEI, C) HA-PEI, D) OA-PEI, E) $\omega$ -amino-HA-PEI and F) $\omega$ -amino-OA-PEI. ....	120
<b>Figure 5.24</b> Confocal microscopy images of HEK 293 cells treated with A) Naked pEGFP-N1, and with polyplexes prepared at N/P ratio-12 using B) 10 KDa PEI, C) HA-PEI, D) OA-PEI, E) $\omega$ -amino-HA-PEI and F) $\omega$ -amino-OA-PEI.. ....	123
<b>Figure 5.25</b> Relative expression of mCTLA4-IGHG1 mRNA after treatment with polyplexes of pAL119-mCTLA4-IGHG1 prepared with A) PEI-10 KDa; B) HA-PEI; C) OA-PEI; D) $\omega$ -amine-HA-PEI and E) $\omega$ -amine-OA-PEI at N/P ratio 12. ....	125
<b>Figure 5.26</b> Relative expression of mCTLA4-IGHG1 mRNA in polyplexes of pAL119-mCTLA4-IGHG1 prepared with A) PEI-10 KDa; B) HA-PEI; C) OA-PEI; D) $\omega$ -amine-HA-PEI and E) $\omega$ -amine-OA-PEI at N/P ratio 12 as suggested by Mean $\Delta C_p$ . ....	126
<b>Figure 5.27</b> Expression fold change of mCTLA4-IGHG1 mRNA in polyplexes of pAL119-mCTLA4-IGHG1 prepared with A) PEI-10 KDa; B) HA-PEI; C) OA-PEI; D) $\omega$ -amine-HA-PEI and E) $\omega$ -amine-OA-PEI at N/P ratio 12 as suggested by $2^{-\Delta\Delta C_p}$ value.....	127
<b>Figure 5.28</b> FACS analysis quantifying EGFP expression in HEK-293 cells in presence of serum (10% FBS). ....	129
<b>Figure 5.29</b> FACS analysis quantifying EGFP expression in HEK-293 cells in absence of serum (10% FBS).....	132
<b>Figure 5.30</b> Transfection efficiency of pEGFP-N1 polyplexes prepared using A) PEI 10KDa, B) HA-PEI, C) OA-PEI, D) $\omega$ -amino-HA-PEI and E) $\omega$ -amino-OA-PEI at N/P ratio-12.....	133
<b>Figure 5.31</b> Size analysis of thyroid glands. ....	135
<b>Figure 5.32</b> Histopathology analysis of thyroid glands. ....	137
<b>Figure 5.33</b> Expression fold change analysis of mCTLA4-IGHG1 mRNA. ....	138